The expanding number of specialized oncology therapeutics available in veterinary oncology can make staying updated on the most recent advances challenging. This article summarizes the mechanism of action, available supporting data, and clinical use of three key veterinary cancer/supportive care therapeutics: Laverdia-CA1, Canalevia-CA1, and Stelfonta. This information will help guide clinical use within your practice and can be incorporated into discussions with clients regarding the newest available options for their dogs with cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cvsm.2023.12.003 | DOI Listing |
Publication Analysis
Top Keywords
veterinary oncology
8
therapies veterinary
4
oncology expanding
4
expanding number
4
number specialized
4
specialized oncology
4
oncology therapeutics
4
therapeutics veterinary
4
oncology staying
4
staying updated
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!